---
title: "Hong Kong's 'New Energy' Tech List Mixes Coconut Water and Beer as 6106 Emerges Solo"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301685432.md"
description: "Only Shanghai Seer (6106.HK) fits Hong Kong's 'new energy hard tech' theme among seven constituents. The industrial automation specialist reported 67.5% H1 revenue growth after Stock Connect inclusion, while beverage, beer and biotech firms dominate the misaligned basket with sector-specific challenges."
datetime: "2026-10-13T09:24:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301685432.md)
  - [en](https://longbridge.com/en/news/301685432.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301685432.md)
generator: "portal-rs"
---

# Hong Kong's 'New Energy' Tech List Mixes Coconut Water and Beer as 6106 Emerges Solo

Hong Kong's so-called 'new energy hard tech' basket has become a case study in misclassification. Shanghai Seer Intelligent Technology (6106.HK) stands as the sole genuine player after its inclusion in Stock Connect boosted liquidity, with H1 revenue surging 67.5% and new orders climbing over 60%. The company recently established a dedicated AI subsidiary to expand industrial automation capabilities.

Other constituents tell a different story. IFBH Limited (6603.HK), a coconut water brand, saw its market value plummet 89% from IPO levels and was removed from Stock Connect due to persistent small-cap status. Budweiser APAC (1876.HK) faces headwinds from RMB 550 million in one-time charges affecting Q3 results. Biotech firms TenNor (6872.HK) and Xuanzhu Biopharm (2575.HK) reported clinical progress and overseas licensing deals unrelated to new energy themes.

The two ETFs (3076.HK, 2848.HK) show negligible trading activity with no discernible news flow. Market participants increasingly question the thematic coherence of this grouping as fundamental drivers diverge sharply across sectors.

### Related Stocks

- [06603.HK](https://longbridge.com/en/quote/06603.HK.md)
- [06106.HK](https://longbridge.com/en/quote/06106.HK.md)
- [06872.HK](https://longbridge.com/en/quote/06872.HK.md)
- [02575.HK](https://longbridge.com/en/quote/02575.HK.md)
- [01876.HK](https://longbridge.com/en/quote/01876.HK.md)
- [03076.HK](https://longbridge.com/en/quote/03076.HK.md)
- [02848.HK](https://longbridge.com/en/quote/02848.HK.md)

## Related News & Research

- [Xuanzhu Biopharmaceutical’s New Bireociclib Indication Included in China’s 2026 NRDL](https://longbridge.com/en/news/305580969.md)
- [Sihuan Pharma Subsidiary Xuanzhu's Bireociclib Gains China Reimbursement for First-Line Breast Cancer Treatment](https://longbridge.com/en/news/305638882.md)
- [TenNor Therapeutics Enrolls First Patient in Phase IIb Rifaquizinone Trial for Prosthetic Joint Infection](https://longbridge.com/en/news/305289463.md)
- [How Profit Collapse In China At Budweiser APAC Has Changed Its Investment Story](https://longbridge.com/en/news/303832326.md)
- [What Budweiser APAC Doubters Saw Before The Drop](https://longbridge.com/en/news/303631906.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**